- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.08. | Sera Prognostics outlines European expansion and new commercial hires while targeting PreTRM Test reimbursement pilots | 1 | Seeking Alpha | ||
| 06.08. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.08. | Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2025 Financial Results | 26 | PR Newswire | SALT LAKE CITY, Aug. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
| 05.06. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.05. | Sera Prognostics names Lee Anderson as new CCO | 1 | Investing.com | ||
| 08.05. | Sera Prognostics ernennt Lee Anderson zum neuen CCO | 9 | Investing.com Deutsch | ||
| SERA PROGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 08.05. | Sera Prognostics, Inc.: Sera Prognostics Appoints Lee Anderson As Chief Commercial Officer | 136 | PR Newswire | Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company®... ► Artikel lesen | |
| 07.05. | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.05. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 07.05. | Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2025 Financial Results | 251 | PR Newswire | SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
| 19.03. | Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2024 Financial Results | 185 | PR Newswire | SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
| 19.03. | Sera Prognostics appoints Jeff Elliott to board | 1 | Investing.com | ||
| 19.03. | SERA PROGNOSTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 19.03. | Sera Prognostics GAAP EPS of -$0.25 misses by $0.01, revenue of $0.02M | 4 | Seeking Alpha | ||
| 19.03. | SERA PROGNOSTICS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 19.03. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.11.24 | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2024 Financial Results | 133 | PR Newswire | SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,600 | 0,00 % | EQS-News: GBC AG: EINLADUNG ZUM GBC INVESTORS CALL - NanoRepro AG | EQS-News: GBC AG
/ Schlagwort(e): Jahresbericht
EINLADUNG ZUM GBC INVESTORS CALL - NanoRepro AG
12.08.2025 / 10:15 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent... ► Artikel lesen | |
| OCUGEN | 0,900 | +0,74 % | Ocugen - Novel cell therapies for retinal diseases | Ocugen's modifier gene therapy (MGT) platform is designed to regulate gene expression to restore visual function across both genetically diverse inherited retinal diseases (IRDs) and retinal conditions... ► Artikel lesen | |
| VIKING THERAPEUTICS | 34,815 | +1,77 % | Doppelschlag mit Viking Therapeutics und Rheinmetall | An der Börse gibt es Momente, in denen wenige Tage über den Erfolg einer ganzen Strategie entscheiden. Wer solche Chancen erkennt und entschlossen handelt, kann in kurzer Zeit außergewöhnliche Ergebnisse... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,460 | -12,77 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| BIOCRYST PHARMACEUTICALS | 7,374 | +3,16 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Departure of Dr. Helen Thackray | RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will... ► Artikel lesen | |
| VAXART | 0,290 | +0,55 % | Vaxart outlines accelerated COVID-19 trial data timeline and plans norovirus Phase IIb pending funding | ||
| REDHILL BIOPHARMA | 1,350 | -4,26 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| IBIO | 0,575 | -9,45 % | XFRA DIVERSE ISINS: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 2,818 | 0,00 % | Arbutus Biopharma Corporation: Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 2,105 | +0,72 % | Cardiff Oncology nach Daten-Dip: Jetzt kaufen? | Cardiff Oncology legt seine lang erwarteten Krebs-Daten vor und der Aktienkurs fährt Achterbahn: Bietet sich für Anleger ein neues Trading-Fenster, oder lässt man jetzt besser die Finger von dem Titel?... ► Artikel lesen | |
| ALDEYRA | 4,542 | -1,33 % | Hagens Berman Sobol Shapiro LLP: Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman | SAN FRANCISCO, April 10, 2025 /PRNewswire/ -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over... ► Artikel lesen | |
| MANNKIND | 3,137 | -1,72 % | MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement | Strengthens MannKind's capital structure with flexible, long-term, non-dilutive fundingMannKind to receive $75 million in cash at closing DANBURY, Conn. and WESTLAKE VILLAGE, Calif. and NEW YORK,... ► Artikel lesen | |
| TRAWS PHARMA | 1,510 | -6,79 % | Traws Pharma, Inc.: Traws Pharma Reports Second Quarter 2025 Results and Business Highlights | Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of... ► Artikel lesen | |
| COHERUS ONCOLOGY | 0,875 | -2,04 % | Coherus Oncology, Inc.: Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 - - Data readouts for CHS-114 and casdozokitug on track for 1H 2026 - - Q2 2025 ending cash, cash equivalents and marketable... ► Artikel lesen |
SERA PROGNOSTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,020 (-0,88 %) liegt der Kurs bei 2,240 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SERA PROGNOSTICS INC finden Sie auf Wallstreet Online.